Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;107:2428-2434
Published online before print May 12, 2003, doi: 10.1161/01.CIR.0000066907.83923.32
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/19/2428    most recent
01.CIR.0000066907.83923.32v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernández-Rodríguez, J.
Right arrow Articles by Cid, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernández-Rodríguez, J.
Right arrow Articles by Cid, M. C.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Angiogenesis
Right arrow Brain Circulation and Metabolism
Right arrow Vasculitis Brain Arteries
Right arrow Other Vascular biology

(Circulation. 2003;107:2428.)
© 2003 American Heart Association, Inc.


Clinical Investigation and Reports

Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis

Angiogenic Activity of Interleukin-6 as a Potential Protective Mechanism

José Hernández-Rodríguez, MD; Marta Segarra, GS; Carme Vilardell, MD; Montse Sánchez, RN; Ana García-Martínez, MD; María-José Esteban, MD; Josep M. Grau, MD; Alvaro Urbano-Márquez, MD; Dolors Colomer, PhD; Hynda K. Kleinman, PhD; Maria C. Cid, MD

From the Vasculitis Research Unit, Departments of Internal Medicine (J.H.-R., M. Segarra, C.V., A.G.-M., M.-J.E., J.M.G., A.U.-M., M.C.C.), Pathology (M. Sánchez), and Hematopathology (D.C.), Hospital Clínic, University of Barcelona, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, and Craniofacial Development and Regeneration Branch (H.K.K.), National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Md.

Correspondence to Maria C. Cid, MD, Department of Internal Medicine, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain. E-mail mccid{at}clinic.ub.es

Background— Patients with giant-cell arteritis (GCA) who develop a strong acute-phase response are at low risk of disease-related ischemic events.

Methods and Results— To assess the potential protective role of proinflammatory cytokines in the development of ischemic events in GCA, we measured tissue expression (66 individuals) and/or circulating levels (80 individuals) of interleukin (IL)-1ß, tumor necrosis factor-{alpha} (TNF-{alpha}), and IL-6 in patients with biopsy-proven GCA. Tissue expression was determined by quantitative real-time polymerase chain reaction and immunohistochemistry. Circulating cytokines were determined by enzyme-linked immunoassay. We found that patients with disease-related ischemic events had lower IL-6 mRNA levels (5.9±2.1 versus 27.6±7.8 relative units, P=0.013), lower IL-6 immunohistochemical expression scores (1.5±0.9 versus 2.7±1, P=0.001), and lower circulating levels of IL-6 (13.6±2.1 versus 24±2.4 pg/mL, P=0.002) than patients without ischemic complications. No significant differences were found for either IL-1ß or TNF-{alpha}. We subsequently investigated direct effects of IL-6 on vessel wall components. We found that IL-6 stimulates endothelial cell proliferation and differentiation into capillary-like structures and induces full angiogenic activity in both ex vivo (aortic ring) and in vivo (chick chorioallantoic membrane) assays.

Conclusions— GCA patients with ischemic complications have lower tissue expression and circulating levels of IL-6 than patients with no ischemic events. IL-6 has relevant direct effects on vascular wall components that might be protective: IL-6 activates a functional program related to angiogenesis that may compensate for ischemia in patients with GCA.


Key Words: angiogenesis • interleukins • ischemia • inflammation




This article has been cited by other articles:


Home page
Ann Rheum DisHome page
M. Segarra, A. Garcia-Martinez, M. Sanchez, J. Hernandez-Rodriguez, E. Lozano, J. M Grau, and M. C Cid
Gelatinase expression and proteolytic activity in giant-cell arteritis
Ann Rheum Dis, November 1, 2007; 66(11): 1429 - 1435.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
M. C. Cid, M. P. Hoffman, J. Hernandez-Rodriguez, M. Segarra, M. Elkin, M. Sanchez, C. Vilardell, A. Garcia-Martinez, M. Pla-Campo, J. M. Grau, et al.
Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis
Rheumatology, November 1, 2006; 45(11): 1356 - 1363.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
J. Y. McClintock and E. M. Wagner
Role of IL-6 in systemic angiogenesis of the lung
J Appl Physiol, September 1, 2005; 99(3): 861 - 866.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. L. Lohr, D. C. Warltier, W. M. Chilian, and D. Weihrauch
Haptoglobin expression and activity during coronary collateralization
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1389 - H1395.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C.-W. Ni, H.-J. Hsieh, Y.-J. Chao, and D. L. Wang
Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow
Am J Physiol Cell Physiol, September 1, 2004; 287(3): C771 - C780.
[Abstract] [Full Text] [PDF]